MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

Therapeutic resistance is a major obstacle to achieving durable clinical responses with targeted therapies, highlighting a need to elucidate the underlying mechanisms responsible for resistance and identify strategies to overcome this challenge. An emerging body of data implicates the tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Caenepeel, Sean, Cooke, Keegan, Wadsworth, Sarah, Huang, Guo, Robert, Lidia, Moreno, Blanca Homet, Parisi, Giulia, Cajulis, Elaina, Kendall, Richard, Beltran, Pedro, Ribas, Antoni, Coxon, Angela, Hughes, Paul E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392287/
https://www.ncbi.nlm.nih.gov/pubmed/28147313
http://dx.doi.org/10.18632/oncotarget.14855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392287/
https://www.ncbi.nlm.nih.gov/pubmed/28147313
http://dx.doi.org/10.18632/oncotarget.14855

Ejemplares similares